Table 2.
Outcomes of tumor response after treatment
| Outcome | RFA + Sorafenib group | Sorafenib group | P-Value |
|---|---|---|---|
| Tumor response in target lesions | |||
| CR | 31.4% (32/102) | 3.1% (4/127) | < 0.001 |
| PR | 57.8% (59/102) | 21.2% (27/127) | < 0.001 |
| SD | 10.8% (11/102) | 40.9% (52/127) | < 0.001 |
| DCR | 100% | 65.3% (83/127) | 0.006 |
| Tumor response in general lesions | |||
| CR | 12.7% (13/102) | 0.8% (1/127) | < 0.001 |
| PR | 46.1% (47/102) | 11.8% (15/127) | < 0.001 |
| SD | 6.8% (7/102) | 29.1% (37/127) | < 0.001 |
| DCR | 65.7% (67/102) | 41.7% (53/127) | < 0.001 |
| OS (mo) | 18.3 ± 1.6 | 14.1 ± 1.1 | 0.03 |
| mOS (mo)* | 14.0 (10.7, 17.2) | 9.0 (6.8, 11.2) | 0.03 |
| Survival rate (%) | |||
| 1 year | 56.9% (58/102) | 42.5% (54/127) | 0.031 |
| 2 year | 34.3% (35/102) | 22.0% (28/127) | 0.048 |
| 3 year | 11.7% (12/102) | 5.5% (7/127) | 0.088 |
Note: Objective Response Rate (ORR), Disease Control Rate (DCR), OS = overall survival, DCR = CR + PR + SD;
*
Data in parentheses are the 95% confidence interval.